Harind Pharmacal Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.40 M
as on 16-11-2024
- Company Age 37 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.20 Cr
as on 16-11-2024
- Satisfied Charges ₹ 8.93 M
as on 16-11-2024
- Revenue 100.83%
(FY 2023)
- Profit 54.79%
(FY 2023)
- Ebitda 5973.39%
(FY 2023)
- Net Worth 16.51%
(FY 2023)
- Total Assets 79.90%
(FY 2023)
About Harind Pharmacal
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.40 M.
The company currently has active open charges totaling ₹5.20 Cr. The company has closed loans amounting to ₹8.93 M, as per Ministry of Corporate Affairs (MCA) records.
Manohar Chandnani, Naran Choudhary, and Raju Patel serve as directors at the Company.
- CIN/LLPIN
U22100MH1987PTC043128
- Company No.
043128
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Apr 1987
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Harind Pharmacal?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manohar Chandnani  | Director | 31-Oct-2017 | Current |
| Naran Choudhary | Director | 04-May-2024 | Current |
| Raju Patel | Director | 04-May-2024 | Current |
Financial Performance and Corporate Structure Insights of Harind Pharmacal.
Harind Pharmacal Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 100.83% increase. The company also saw a substantial improvement in profitability, with a 54.79% increase in profit. The company's net worth Soared by an impressive increase of 16.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Harind Pharmacal?
In 2022, Harind Pharmacal had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Jun 2024 | ₹5.20 Cr | Open |
The Saraswat Co-Operative Bank Ltd. Creation Date: 05 Oct 2010 | ₹2.00 M | Satisfied |
The Saraswat Co-Op. Bank Ltd. Creation Date: 27 Mar 2002 | ₹5.30 M | Satisfied |
How Many Employees Work at Harind Pharmacal?
Unlock and access historical data on people associated with Harind Pharmacal, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Harind Pharmacal, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Harind Pharmacal's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
